Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination

1992 ◽  
Vol 73 (2) ◽  
pp. 94-100 ◽  
Author(s):  
T.K. Young ◽  
S. Mirdad
2017 ◽  
Vol 15 (11-12) ◽  
pp. 315
Author(s):  
A.S. Gunardi

Based on a tuberculosis prevalence survey with the assistance of WHO in 1962 - 1965 in the areas fogyakarta and Malang where were found a prevalence of tuberculin sensitivity of 40,6% at the age 10-14 years, a prevalence of bac- teriologically confirmed cases of 0.6% and those with pulmonary shadows 3.6%, a workshop in Ciloto was hold (January 1969), with the following results :a. BCG vaccination without prior tuberculin test to children of 0-14 years of age.b. Case finding and treatment to those with sputum ”afb” positive.c. Health education to the people.In Pelita I priority was given to BCG vaccination with a target of 55 million of which a 75% coverage will be expected particularly in Java and Bali.For Pelita II BCG vaccination policy will be changed. To achieve a more realistic target and to have the most susceptible (high risk) ages vaccinated, every child should have a recent BCG vaccination before entering puberty and to vaccinate children early in life, 0-1 year. Only primary vaccination will be done during Pelita II while revaccination will be performed in Pelita III. As performers will be the smallpox vaccinators in a simultaneous vaccination programme with other vaccines.Case finding and treatment, and Health education will be improved in Pelita II because the health infra structure (organization) and community participation was below expectation in Pelita I; it will be integrated into the existig health activities. Treatment will only be given to patients with bacteriologically confirmed sputum, and free of charge.


Tubercle ◽  
1983 ◽  
Vol 64 (4) ◽  
pp. 255-263 ◽  
Author(s):  
M.A. Bleiker ◽  
J. Meijert ◽  
K. Stýblo ◽  
Ian Sutherland

Author(s):  
Sujatha S. ◽  
Rebecca Samson ◽  
Christopher Amalraj ◽  
Sundaresan Sundaresan

Neglected pain in neonates leads to various ill effects and it can be prevented by using simple and safe non-pharmacological pain relieving measures. Pharmacologic agents are not recommended in neonates for acute pain due toinvasive procedures however, administration of 24% oralsucrose solutionis found to be effective. The objective of this study was to assess the efficacy of 24%oral sucrose in combination with Facilitated tucking during BCG Vaccination through intradermalroute in term neonates which is not done elsewhere. Fifty five healthy term neonates who fulfilled the inclusion criteria such as gestational age above 37 weeks, within 24 hoursof birth age, and neonates delivered only through spontaneous vaginal delivery were included in the study. The study intervention consists of administration of 2 ml of oral 24% sucrose 2 minutes before BCG Vaccination through intradermal route and Facilitated tuckingat the time of vaccination. The primary outcome measure of cumulative NIPS score at 0, 3,5 minuteswas not significant in both the study groups. Whereas there was significant reduction in the level of pain and mean cry time in the neonates of sucrose group. Heart rateand oxygen saturation after intradermal injection also showed significant (p less than 0.001) differenceamong the neonates, who received 24% of oral sucroseand Facilitated tucking than for neonates of control group. Thus oral (24%)sucrose solution given 2 minutes before injection was effective in reducing level of neonatal pain following Intradermal Vaccination. It is a simple, safe and fast acting analgesic and should be considered for minor invasive procedures in term neonates which last for 5-7minutes.


Sign in / Sign up

Export Citation Format

Share Document